Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board
Retrieved on:
Monday, January 17, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Linda, Clemson University, EDTA, Green College, Hotel des Indes (The Hague), VP, MAA, Industry, Therapy, Hospital, Grünenthal, LLC, Yuri, Health authority, NDA, Investment, Technology, Ageing, Conference, Pangborn Sensory Science Symposium, CTAS, Degenerative disease, Corporation, MBA, Cardiovascular disease, Health, Associate, Doctor of Philosophy, NICE, VC, Head, Elastin, United States Air Force Scientific Advisory Board, Patient, CMO, Chronic kidney disease, Reader, Mentorship, University, III, Board, Harvard Medical School, Winnipeg Regional Health Authority, Seminal vesicles, CEO, University of California, San Diego, MD, Calcification, Pharmaceutical industry, Management, Research, Brigham, Pediatrics, Medicine, Elastrin Therapeutics Inc., KIZOO, ELASTRIN THERAPEUTICS INC., KIZOO
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
Key Points:
- Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
- We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
- Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
- Elastrin Therapeutics Scientific Advisory Board is comprised of:
Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.